What is Chemsex? Epidemiology, Harms & Impacts

Gary Whitlock, MD, PhD
Consultant Physician
HIV and Sexual Health Service Director, 56 Dean Street
Chelsea & Westminster Hospital NHS Foundation Trust
London, UK

Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2023. All rights reserved.



CME VIDEOTop of page

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Survey

About the Presenters:Top of page

Dr Gary Whitlock is a consultant physician in HIV and sexual health and Service Director at 56 Dean Street, part of Chelsea and Westminster Hospital. Dr. Whitlock has a PhD in physiology from the University of Cambridge and qualified from Nottingham University in medicine. He runs the high-resolution anoscopy service at 56 Dean Street. His research interests include gay men’s sexual health, HIV prevention and service evaluation.

Learning Objectives: Top of page

At the completion of this educational session, learners will:
1. Be able to define chemsex.
2. Be aware of its epidemiology.
3. Understand it's associations with sexual practices, STIs and HIV infection and potential health impacts to chems users.
4. Be aware of examples of chem sex support services.

CME Information:Top of page


This CME activity has approved for AMA PRA Category 1 Credit™ for August 16, 2023, as a live activity.  This activity will also be available as an enduring activity from August 23, 2023, through August 15, 2026.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement:Top of page

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun (Course Director/Planner) has no relevant financial relationships to disclose.
- Dr. Roy M. Gulick (Moderator) has no relevant financial relationships to disclose.
- Dr. Gary Whitlock (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Advisor to ViiV and GSK. Dr. Whitlock submitted his slides in advance for adequate peer review and supported his presentation and clinical recommendations with the best available evidence from the medical literature. All relevant financial relationships were mitigated.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

You must be logged in to post a comment. Login | Register